Monopar Therapeutics Cash Flow Statement
MNPR|6 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Monopar Therapeutics used $12M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Net Income | -$13.7M | -$8.4M | -$10.5M | -$4.2M | -$16.6M | -$1.2M |
| Operating Cash Flow | -$12.2M | -$7.9M | -$7.2M | -$3.0M | -$2.6M | -$1.2M |
| Share Buybacks | $35.0M | - | - | - | - | - |